{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:15:29Z","timestamp":1782663329807,"version":"3.54.5"},"reference-count":74,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Psychedelic Medicine"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>\n                    <jats:bold>Abstract<\/jats:bold>\n                  <\/jats:title>\n                  <jats:p>The reemergence of psychedelic medicines as clinical treatments has generated considerable interest in both professional and popular arenas. Although evidence is promising for psychedelic-assisted therapy (PAT), there is much that is not yet known and needs to be researched so as to understand how to safely and effectively utilize PAT in clinical populations and to most effectively deploy PAT to patients. In addition, non-clinical stakeholders introduce interests and agendas that may differ from those of clinicians. This article reviews the history of how psychedelics were initially outlawed and then introduces research questions that will help to fill these gaps in knowledge.<\/jats:p>","DOI":"10.1089\/psymed.2023.0017","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:41:22Z","timestamp":1693215682000},"page":"198-209","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda"],"prefix":"10.1177","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5552-7078","authenticated-orcid":false,"given":"Andrew","family":"Penn","sequence":"first","affiliation":[{"name":"Department of Community Health Systems, University of California, San Francisco School of Nursing, San Francisco, California, USA."},{"name":"San Francisco Veterans Administration Hospital, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Yehuda","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mt Sinai, New York, New York, USA."},{"name":"James J Peters Veterans Administration Medical Center, Bronx, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010035"},{"key":"e_1_3_3_3_2","unstructured":"Bodie A. Off Label Use of Prescription Drugs Congressional Research Services Report R45792; February 23 2021. Available from: https:\/\/sgp.fas.org\/crs\/misc\/R45792.pdf [Last accessed: January13 2023]."},{"key":"e_1_3_3_4_2","unstructured":"The Federal Register. Withdrawal of Approval of an Application or Abbreviated Application 21 CFR 314.150; April 28 1993. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-D\/part-314\/subpart-D\/section-314.150 [Last accessed: January20 2023]."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.02.018"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.863088"},{"key":"e_1_3_3_8_2","volume-title":"Psychedelic Drugs as Treatment Agents (in press)","author":"Yehuda R","unstructured":"Yehuda R, , Leptow LA, , Bonnano PA, et al. Neurobiology of Mental Illness, 6th ed. In: Psychedelic Drugs as Treatment Agents (in press). (Charney DS, , Nestler EJ. eds.) Chapter 74. Oxford University Press: Oxford, United Kingdom; In Press.","edition":"6"},{"key":"e_1_3_3_9_2","unstructured":"Doblin R. Multidisciplinary Association for Psychedelics Studies: Interview with Rick Doblin Psychedelic Pioneer and Founder of MAPS (Video); 2014. Available from: https:\/\/maps.org\/2014\/07\/01\/interview-with-rick-doblin-psychedelic-pioneer-founder-of-maps\/ [Last accessed: January5 2023]."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.040"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721004207"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1353\/book.3470"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1957.tb12312.x"},{"issue":"23","key":"e_1_3_3_14_2","first-page":"1200","article-title":"The use of lysergic acid diethylamide (LSD) in psychotherapy","volume":"91","author":"Baker ED.","year":"1964","unstructured":"Baker ED. The use of lysergic acid diethylamide (LSD) in psychotherapy. Can Med Assoc J, 1964; 91(23):1200\u20131202.","journal-title":"Can Med Assoc J"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13249"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/shm\/15.1.137"},{"key":"e_1_3_3_17_2","volume-title":"Before Prozac:","author":"Shorter E.","year":"2009","unstructured":"Shorter E. Before Prozac:. The Troubled History of Mood Disorders in Psychiatry. Oxford University Press: Oxford, United Kingdom; 2009."},{"key":"e_1_3_3_18_2","unstructured":"Food and Drug Administration. Drug Efficacy Safety Investigation Silver Spring MD; 2022 Available from: https:\/\/www.fda.gov\/drugs\/enforcement-activities-fda\/drug-efficacy-study-implementation-desi [Last accessed: January5 2023]."},{"key":"e_1_3_3_19_2","unstructured":"Leary T. The Psychedelic Experience; A Manual Based on the Tibetan Book of the Dead. Citadel Press: New York NY; 1968."},{"key":"e_1_3_3_20_2","unstructured":"Wolfe T. The Electric Kool-Aid Acid Test. Picador: New York NY; 1968."},{"key":"e_1_3_3_21_2","unstructured":"Gissen-Stanley R Davis T. Owsley and Me: My LSD Family. Monkfish Book Publishing Company: Rhinebeck NY; 2012."},{"key":"e_1_3_3_22_2","unstructured":"Grimes W. Nicholas Sand Chemist Who Sought to Bring LSD to the World Dies at 75 New York Times. May 14 2017. Available from: https:\/\/www.nytimes.com\/2017\/05\/12\/us\/nicholas-sand-chemist-who-sought-to-bring-lsd-to-the-world-dies-at-75.html"},{"key":"e_1_3_3_23_2","unstructured":"ABC Australia (Director) The Final Days of Timothy Leary High Priest of LSD (film). Ultimo Australia; 1996. Available from: https:\/\/www.journeyman.tv\/film_documents\/235\/transcript\/ [Last accessed: January5 2023]."},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","unstructured":"Hartogsohn I. American Trip: Set Setting and the Psychedelic Experience in the 20th Century. MIT Press: Cambridge MA; 2020.","DOI":"10.7551\/mitpress\/11888.001.0001"},{"key":"e_1_3_3_25_2","first-page":"68","volume-title":"Handbook of Medical Hallucinogens","author":"Mangini M.","year":"2021","unstructured":"Mangini M. A Short, Strange Trip: LSD Politics, Publicity, and Mythology From Discovery to Criminalization. In: Handbook of Medical Hallucinogens. (Grob CS, Grigsby J. eds) Guilford Press: New York, NY; 2021; pp. 68\u201394."},{"key":"e_1_3_3_26_2","unstructured":"Office of the Law Revision Council United States Code. An Act to Amend the Federal Food Drug and Cosmetic Act to Increase the Penalties [H. R. I4096] for Unlawful Acts Involving Lysergic Acid Diethylamide (LSD) and Other Depressant and Stimulant Drugs and for Other Purposes. Public Law 90-639; 1968. Available from: https:\/\/uscode.house.gov\/statutes\/pl\/90\/638.pdf [Last accessed: February26 2023]."},{"key":"e_1_3_3_27_2","unstructured":"Drug Enforcement Administration. Controlled Substance Act. Washington DC; 1970. Available from: https:\/\/www.dea.gov\/drug-information\/csa [Last accessed: January5 2023]."},{"key":"e_1_3_3_28_2","unstructured":"Inouye D Goldwater B. Project MKULTRA the CIA's Program of Research in Behavioral Modification Joint Hearing Before the Select Committee on Intelligence 95th Congress; August 3 1977. Available from: https:\/\/www.intelligence.senate.gov\/sites\/default\/files\/hearings\/95mkultra.pdf [Last accessed: January14 2023]."},{"issue":"5639","key":"e_1_3_3_29_2","first-page":"1479","article-title":"Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (\u201cEcstasy\u201d)","volume":"301","author":"Ricaurte GA","year":"2003","unstructured":"Ricaurte GA, , Yuan J, , Hatzidimitriou G, et al. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (\u201cEcstasy\u201d). Science 2002 (5590):2260\u20132263. [10.1126\/science.1074501] (Retraction published Ricaurte GA, Yuan J, Hatzidimitriou G, et al. Science, 2003; 301(5639):1479). [doi: 10.1126\/science.301.5639.1479b].","journal-title":"Science 2002 (5590):2260\u20132263. [10.1126\/science.1074501] (Retraction published Ricaurte GA, Yuan J, Hatzidimitriou G, et al. Science"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000253551"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7742(09)88010-0"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950020009001"},{"key":"e_1_3_3_33_2","unstructured":"Sessa B. The Psychedelic Renaissance: Reassessing the Role of Psychedelic Drugs in 21st Century Psychiatry and Society. Muswell Hill Press: London; 2013."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0457-5"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_3_38_2","doi-asserted-by":"crossref","unstructured":"Kupferschmidt K. All clear on the decisive trial of ecstasy for PTSD patients. Science 2017; doi: 10.1126\/science.aap7739. Available from: https:\/\/www.science.org\/content\/article\/all-clear-decisive-trial-ecstasy-ptsd-patients [Last accessed: February3 2023].","DOI":"10.1126\/science.aap7739"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-02872-9"},{"key":"e_1_3_3_40_2","unstructured":"Food and Drug Administration Breakthrough Therapy Silver Spring MD; 2018. Available from: https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/breakthrough-therapy [Last accessed: January5 2023]."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0b013e31817bd7c9"},{"key":"e_1_3_3_42_2","doi-asserted-by":"crossref","unstructured":"Yehuda R. Treating Trauma Survivors with PTSD (1st ed.) (Yehuda R. ed.) American Psychiatric Publishing: Washington DC; 2002; pp. IX\u2013XVI.","DOI":"10.1176\/appi.books.9781615377008"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.36921"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1772054"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.0099"},{"issue":"1","key":"e_1_3_3_47_2","first-page":"1","article-title":"Varenicline and suicide: Reconsidered and reconciled","volume":"18","author":"Niaura R.","year":"2016","unstructured":"Niaura R. Varenicline and suicide: Reconsidered and reconciled. Nicotine Tobacco Res, 2016; 18(1):1; doi: 10.1093\/ntr\/ntv247","journal-title":"Nicotine Tobacco Res"},{"key":"e_1_3_3_48_2","unstructured":"Kane SP. Varenicline ClinCalc DrugStats Database Version 2022.08. ClinCalc; 2022. Available from: https:\/\/clincalc.com\/DrugStats\/Drugs\/Varenicline [Last accessed: November21 2022]."},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.07.004"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.08.090"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1824-6"},{"key":"e_1_3_3_52_2","unstructured":"Kary T. Psychedelics Can Treat PTSD So Should They Be Given to Soldiers? Bloomberg; November 7 2022. Available from: https:\/\/www.bloomberg.com\/news\/newsletters\/2022-11-07\/psychedelics-for-the-military-debate-grows-over-treatments-for-ptsd [Last accessed: January13 2023]."},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1995.03950240066012"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40479-021-00155-9"},{"key":"e_1_3_3_55_2","unstructured":"Grof S. LSD Psychotherapy. MAPS Press: Santa Cruz CA; 1980."},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.873279"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1020505"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104706"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2021_266"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1025726"},{"key":"e_1_3_3_61_2","unstructured":"Study Comparing Two Versus Three Active MDMA-Assisted Sessions in U.S. Military Veterans With Chronic PTSD (MPVA6) NCT04784143. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04784143 [Last accessed: July15 2023]."},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.824077"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231167848"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263252"},{"key":"e_1_3_3_67_2","unstructured":"Shulgin A Shulgin A. PIHKAL: Phenylethylamines I Have Known and Loved. Transform Press: Berkeley CA; 1991"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109399"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2022.0017"},{"key":"e_1_3_3_70_2","unstructured":"Oregon Health Authority (ND) Oregon Psilocybin Services. Available from: https:\/\/www.oregon.gov\/oha\/ph\/preventionwellness\/pages\/oregon-psilocybin-services.aspx [Last accessed: January5 2023]."},{"key":"e_1_3_3_71_2","unstructured":"Psychedelic Alpha. Psychedelic Legalization and Legislation Tracker Psychedelic Alpha; 2023. Available from: https:\/\/psychedelicalpha.com\/data\/psychedelic-laws [Last accessed: January19 2023]."},{"key":"e_1_3_3_72_2","unstructured":"Bloomberg News Psychedelic Therapeutics Market Worth $ 8.31 Billion by 2028; 2022. Available from: https:\/\/www.bloomberg.com\/press-releases\/2022-07-18\/psychedelic-therapeutics-market-worth-8-31-billion-by-2028-exclusive-report-by-insightace-analytic [Last accessed: January5 2023]."},{"key":"e_1_3_3_73_2","unstructured":"Pollan M. How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness Dying Addiction Depression and Transcendence. Penguin Books: New York NY; 2019."},{"key":"e_1_3_3_74_2","unstructured":"North H. Sophrosyne: Self-Knowledge and Self-Restraint in Greek Literature. Cornell University Press: Ithaca NY; 1966."},{"key":"e_1_3_3_75_2","volume-title":"In: Michele de Montaigne\u2014The Complete Essays (Screech MA, ed. and Trans)","author":"Montaigne M.","year":"1588","unstructured":"Montaigne M. Of Experience. In: Michele de Montaigne\u2014The Complete Essays (Screech MA, ed. and Trans). Penguin Classics: London;. 1588."}],"container-title":["Psychedelic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/psymed.2023.0017","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/psymed.2023.0017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/psymed.2023.0017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:27:14Z","timestamp":1777685234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/psymed.2023.0017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12,1]]}},"alternative-id":["10.1089\/psymed.2023.0017"],"URL":"https:\/\/doi.org\/10.1089\/psymed.2023.0017","relation":{},"ISSN":["2831-4425","2831-4433"],"issn-type":[{"value":"2831-4425","type":"print"},{"value":"2831-4433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}